Skip to main content

Table 1 Patient characteristics at enrollment

From: Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study

Patient Age
(years)
Sex Country of origin Race Relevant prior treatment Current treatment Historical disease features Age at ulcer onset (years) Primary outcome
1 59 F USA Caucasian Abatacept
Adalimumab
Azathioprine
Colchicine
Glucocorticoids
Infliximab
Azathioprine Oral and genital ulcers, GI ulcers, skin pustules, arthralgias 7 Treatment failure
2 19 F USA Caucasian Colchicine
Glucocorticoids
Sulfasalazine
Colchicine
Sulfasalazine
Prednisone (15 mg/day)
Oral and genital ulcers, GI ulcers, thrombophlebitis, arthralgias, skin pustules, folliculitis, pathergy, HLA-B51-positive 16 Complete response
3 40 F USA Mixed Colchicine,
Hydroxychloroquine
Glucocorticoids
Colchicine
Hydroxychloroquine
Oral and genital ulcers, skin pustules, arthritis 38 Partial response
4 30 F USA Caucasian Colchicine
Glucocorticoids
None Oral and genital ulcers, skin pustules, anterior uveitis, arthritis 2 Complete response
5 26 F USA Caucasian Azathioprine
Glucocorticoids
Azathioprine Oral and genital ulcers, GI ulcers, skin pustules, deep vein thrombosis 21 Treatment failure
6 36 M Ethiopia African Colchicine
Glucocorticoids
Prednisone (20 mg/day) Oral and genital ulcers, skin pustules, panuveitis, arthritis 31 Partial response
  1. Active disease features at the time of enrollment are highlighted in bold